Nasdaq · CIK 0001191070
NEUP Neuphoria Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jan 21, 2026. Close $3.36 on Oct 9, 2026, +2% from the 52-week low and -82% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
NEUPOct 9, 2026 · close 3.36
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Neuphoria Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Lynx1 Capital Management LP owner buy | $3.3M 639,110 shares | +271% | - |
Transactions
The last 12 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Peter Miles Winston Davies director | AGrant or award Restricted Stock Unitsderivative | +8,537 | $0.00 | $0 | 15,320 | Jan 21, 2026 |
| Jan 20, 2026 | Alan Fisher director | AGrant or award Restricted Stock Unitsderivative | +17,073 | $0.00 | $0 | 30,731 | Jan 21, 2026 |
| Jan 20, 2026 | Jane Ryan director | AGrant or award Restricted Stock Unitsderivative | +8,537 | $0.00 | $0 | 15,550 | Jan 21, 2026 |
| Jan 20, 2026 | David Ian Wilson director | AGrant or award Restricted Stock Unitsderivative | +8,537 | $0.00 | $0 | 15,412 | Jan 21, 2026 |
| Oct 21, 2025 | Lynx1 Capital Management LP owner | POpen-market purchase Common stock, $0.00001 par value per shareindirect: See footnote | +639,110 | $5.14 | $3.3M | 875,328 | Oct 23, 2025 |
| Aug 27, 2025 | Spyros Papapetropoulos President and CEO | AGrant or award Employee Stock Option (Right-to- Buy)derivative | +34,559 | $8.27 | $286k | 74,088 | Sep 2, 2025 |
| Apr 16, 2025 | Spyros Papapetropoulos President and CEO | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +27,000 | $5.16 | $139k | 39,529 | May 19, 2025 |
| Apr 16, 2025 | Peter Miles Winston Davies director | AGrant or award Restricted Stock Unitsderivative | +6,783 | $0.00 | $0 | 6,783 | Apr 18, 2025 |
| Apr 16, 2025 | Alan Fisher director | AGrant or award Restricted Stock Unitsderivative | +13,566 | $0.00 | $0 | 13,658 | Apr 18, 2025 |
| Apr 16, 2025 | David Ian Wilson director | AGrant or award Restricted Stock Unitsderivative | +6,783 | $0.00 | $0 | 6,875 | Apr 18, 2025 |
| Apr 16, 2025 | Jane Ryan director | AGrant or award Restricted Stock Unitsderivative | +6,783 | $0.00 | $0 | 7,013 | Apr 18, 2025 |
| Apr 16, 2025 | Spyros Papapetropoulos President and CEO | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +270,000 | $5.16 | $1.4M | 282,529 | Apr 18, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Peter Miles Winston Daviesdirector
- Alan Fisherdirector
- Lynx1 Capital Management LPowner
- Spyros PapapetropoulosPresident and CEO
- Jane Ryandirector
- David Ian Wilsondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.